GI GILD Gilead Sciences Inc. Loading... : Bullish and Bearish Analyst Opinions

Author notes healthcare stocks are setting up in a strong uptrend and lists XLV's top holdings.

Author compliments the portfolio but admits unfamiliarity with AKAM and GILD.

Merck and Gilead drugs are set for wider use in eastern Democratic Republic of Congo to combat.

Gilead reported sales growth that beat expectations driven by strong performance of its HIV.

Notes swing to loss on R&D

Gilead raised its full-year sales guidance driven by strong HIV portfolio, Tredelvey, and Livdelzi performance, indicating a positive outlook and strong execution.

Gilead Sciences reports Q2 2026 revenue above estimates but a wider adjusted loss per share.

Gilead guides full-year product sales in line with expectations but cuts its Veklury revenue.

Gilead Sciences reports Q2 revenue above estimates with adjusted loss narrower than expected.

Cheap, ignored, strong oncology and HIV.

Niktimbo is growing by gaining market share in third-line plus myelofibrosis, but the recent data from other companies like Gilead's momelotinib could heighten competition in this setting. — With a third of the market, Incyte faces direct competition from Gilead's momelotinib and possibly others; maintaining this share is key to the heme-onc portfolio's growth.

Gilead and Merck announced that their experimental long-acting HIV pill combining two drugs met.

Gilead and Merck report positive Phase 3 results for their once-weekly oral HIV treatment.

Management is confident in its commercial execution and the durability of its HIV franchise, including a raised full-year 2026 revenue guidance by $400 million and a $1 billion Yes2Go target.

Gilead has strong HIV franchise and pipeline.

Biogen and Gilead are attractive.

Hold Gilead for its franchises.

GILD passed the author's strict fundamental screen, boasting a 32% FCF margin, 39% R&D intensity, and a 48% P/E discount to its 5-year average. High free cash flow and significant R&D investment combined with a massive historical discount position it to successfully navigate the patent cliff. Buy GILD as a fundamentally sound survivor of the upcoming patent cycle. General pipeline failures or inability to commercialize R&D investments effectively.

Mercier highlights the launch of Lenacapavir, a "twice-yearly injection" for HIV prevention with "99.9% efficacy," and notes the company is building out its oncology platform in breast cancer and lymphoma. The shift from daily pills to a biannual injection represents a massive quality-of-life improvement for patients, creating a strong competitive moat against competitors like GSK (whose injectable is every 2 months). The rapid voluntary licensing for developing nations mitigates global drug pricing/IP criticism (ESG risk), allowing Gilead to protect high-margin pricing in the US and EU while securing its status as the global standard of care. Long GILD as it solidifies its dominance in the HIV market through superior delivery mechanisms and diversifies revenue via its growing oncology pipeline. Regulatory hurdles in new oncology indications, patent expirations on legacy HIV drugs, or safety issues emerging with long-acting formulations.

Gilead (GILD) agreed to buy Arcellx (ACLX) for $7.8B. ACLX rallied 77%. This confirms that Big Pharma is actively deploying cash for pipeline acquisition. While the ACLX trade is done, it signals that small/mid-cap biotech with promising late-stage data are prime targets. WATCH. Look for other biotech names with strong clinical data in oncology/cell therapy as potential targets. M&A regulation could stifle future deals.

Gilead's management has provided a clear forward-looking synergy target.

Moderna's flu vaccine (mRNA-1010) was refused filing by the FDA, but is progressing in Europe, Canada, and Australia. The company highlights a potential strain mismatch in the US vs. Northern Hemisphere, positioning its mRNA platform as a solution for better strain matching. — If Moderna secures approvals abroad, it could gain share in international markets while incumbents like Pfizer and GSK are locked into traditional strain selection, leading to a competitive advantage in vaccine efficacy.

Management's tone is bullish, with multiple catalysts (Yes2Go ramp, Trodelvy launches, anitocel) and reaffirmed discipline, positioning 2026 as a year of accelerated growth.

Gilead's (GILD) hemodiafiltration technology, which uses high-volume replacement fluid, is being used in clinical studies and is expected to be a significant growth driver for DaVita's dialysis technology. The impact was mentioned as 'possible revenue recognition' but more importantly, the technology uptake will be driven by the upcoming HeMo study data. — If HeMo study data (with Gilead's tech) is positive, CMS will issue a national coverage determination in 2026, unlocking a large new market for GILD's technology and DaVita's implementation.

Agilent's new CTO from Thermo Fisher (TMO) and manufacturing leader from Gilead (GILD) signal a strategic push to bolster R&D and operational efficiency. This could intensify competition in the analytical instruments space. — Leadership hires from a direct competitor and a major pharma customer indicate Agilent is planning for a more aggressive, innovation-led growth phase.